Contrarily, other studies demonstrated an increased sensitivity of cancer cells with IDH mutations to several drugs, including alkylating agents [83], inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) [84], and inhibitors of poly ADP ribose polymerase (PARP) [85]. Here, IDH2 is linked to cancer.